RxDoctor Payments Data

Clancy Howard, MD

Nephrology · Denver, CONPI 1336121623

Payments from drug & device makers

$736in general payments, 2019–2025

Across 21 payments — averaging $35.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$125
  • Calliditas Therapeutics US Inc.$113
  • AstraZeneca$110
  • Novartis$110
  • Nxstage Medical, Inc.$88
  • Amgen$53
  • plus $138 from 4 others

What the payments were for

  • Food & beverage$62785%
  • Education$10915%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$736 in reported general payments places this provider in the 45th percentile of 152 nephrology providers in Colorado.

See all nephrology providers in Colorado

Medicare billing

Part B allowed, 2024
$130,909
Medicare patients
233
Services billed
1,155

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$34,331
FarxigaDapagliflozin Propanediol12$19,278
KerendiaFinerenone12$14,659
Mycophenolic AcidMycophenolate Sodium11$6,528
Sevelamer Carbonate28$5,981
Clonidine16$2,012
Gentamicin Sulfate19$893
Potassium Chloride43$803
Furosemide79$659
Carvedilol65$596
Amlodipine Besylate80$572
Losartan Potassium56$528
Lisinopril62$519
Nebivolol Hcl11$388
Hydralazine Hcl16$327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$110$19,27812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 152 nephrology providers in Colorado.

Other nephrology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →